EN DE
Watch ASIAMEDIC LIMITED for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ASIAMEDIC LIMITED (505) fair value: what the stock is really worth

As of Nov 2, 2026: fair value (intrinsic value) of ASIAMEDIC LIMITED stock S$0.02, price S$0.02, upside +12.0%, quality 56 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SG0505000059

AL ASIAMEDIC LIMITED logo Thin data Nov 13, 2026

ASIAMEDIC LIMITED

505 · SG

Solid company, but only slightly cheap (11% below fair value) and price moving sideways: meets 1 of 3 rules.

Get notified free when this changes
Fair value 0.0202 SGD · Undervalued 
Healthy Growth (revenue 5y +18.2 %/yr in SGD) 
Low debt 
Generates free cash flow 
Ranks above peers (10/12) 
Even on cautious assumptions the value is 2% above the price (0.0184 SGD). 
Quality 56/100 
Price moving sideways (no uptrend) 
Thin margins · 5.7% net margin (TTM) 
Narrow moat 40/100 · thin data
Thin data 
Watch ASIAMEDIC LIMITED for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.0270 SGD 0.0090 SGD Fair Value 0.0202 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range 0.0090 SGD – 0.0270 SGD · fair‑value band 0.0184 SGD – 0.0238 SGD · the 0.0180 SGD price screens below the 0.0202 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow ASIAMEDIC in your weekly email

Every Wednesday you see whether ASIAMEDIC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AsiaMedic Limited provides healthcare services in Singapore.

Show moreShow less

It offers diagnostic imaging and radiology services, such as magnetic resonance imaging, computed tomography, bone densitometry, ultrasound, mammography, and x-ray imaging services, as well as cardiovascular, musculoskeletal, ear, nose and throat, breast, body, and neuroradiology assessments to general practitioners, specialists, and hospitals; and positron emission tomography and computed tomography scans for cardiac and cancer imaging.

The company also provides primary healthcare services; medical aesthetic services, including laser skin rejuvenation, non-surgical facelifts, dermal fillers, body contouring, and skincare solutions; medical arrangement, travel medical concierge, diagnostic scan, wellness, medical evacuation, and visa services; and pharmaceuticals and aesthetic products.

In addition, it operates family clinics and a boutique aesthetic clinic. The company was incorporated in 1974 and is based in Singapore.

Stock analysis

ASIAMEDIC LIMITED (505) currently trades at 0.0180 SGD, while our model-based Fair Value estimate is 0.0202 SGD, implying the stock looks roughly 11% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 0.0400 SGD per share, and 17 of the 24 models we run sit above the 0.0180 SGD price.

Bear case: the Asset-Based group reads lowest at 0.0100 SGD, and 7 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.0184 SGD (bear) to 0.0238 SGD (bull), the price of 0.0180 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

ASIAMEDIC LIMITED reported revenue of 35.2M SGD in FY2025 versus 18.3M SGD in FY2021, a compound +17.9%/yr. Reported net income was 2.0M SGD in FY2025, compounding +29.7%/yr from FY2021.

Key figures

Market cap 20.3M SGD (≈ $15.8M) Micro · P/S ratio 0.57 · Net margin 5.7% · Return on equity 11.7% · Return on assets (EBIT) 2.3% (5-year average) · Operating margin 0.7% · Revenue (TTM) 34.9M SGD · Revenue growth (YoY) −2.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 12%, 505 screens cheaper than that median.

Fair Value models

Bear 0.0184 SGD Fair Value 0.0202 SGD Bull 0.0238 SGD
Price 0.0180 SGD · Upside +12.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.0200 SGD 0.0300 SGD 0.0600 SGD 75
5Y EBITDA Exit 0.0300 SGD 0.0500 SGD 0.0700 SGD 74
Growth DCF 0.0200 SGD 0.0300 SGD 0.0600 SGD 74
All 24 models by family
DCF Models
FCF DCF 0.0200 SGD 0.0300 SGD 0.0600 SGD 75
Owner Earnings 0.0400 SGD 0.0700 SGD 0.1300 SGD 72
5Y Revenue Exit 0.0100 SGD 0.0100 SGD 0.0200 SGD 70
5Y EBITDA Exit 0.0300 SGD 0.0500 SGD 0.0700 SGD 74
5Y P/E Exit 0.0300 SGD 0.0500 SGD 0.0800 SGD 68
10Y Revenue Exit 0.0100 SGD 0.0200 SGD 0.0200 SGD 67
10Y EBITDA Exit 0.0200 SGD 0.0400 SGD 0.0700 SGD 65
10Y P/E Exit 0.0200 SGD 0.0400 SGD 0.0700 SGD 60
Earnings-Based
Graham-Dodd 0.0100 SGD 0.0600 SGD 0.0800 SGD 64
Lynch FV 0.0200 SGD 0.0200 SGD 0.0300 SGD 61
PEG = 1.0 0.0200 SGD 0.0200 SGD 0.0300 SGD 57
EPV n/a 0.0100 SGD 0.0100 SGD 69
Multiples
P/E Multiple 0.0300 SGD 0.0400 SGD 0.0500 SGD 63
P/S Multiple 0.0200 SGD 0.0300 SGD 0.0400 SGD 56
P/B Multiple 0.0100 SGD 0.0200 SGD 0.0200 SGD 55
EV/EBIT 0.0100 SGD 0.0100 SGD 0.0100 SGD 65
EV/EBITDA 0.0300 SGD 0.0400 SGD 0.0500 SGD 67
EV/Revenue 0.0100 SGD 0.0100 SGD 0.0100 SGD 53
Asset-Based
NCAV (Graham) 0.0100 SGD 0.0100 SGD 0.0100 SGD 55
Growth DCF
Growth DCF 0.0200 SGD 0.0300 SGD 0.0600 SGD 74
Rev-Margin DCF 0.0100 SGD 0.0100 SGD 0.0200 SGD 70
Economic Profit
Residual Income 0.0100 SGD 0.0200 SGD 0.0200 SGD 71
ROIC Compounder n/a 0.0100 SGD 0.0100 SGD 68
Growth Earnings
Growth-Adj P/E 0.0300 SGD 0.0400 SGD 0.0500 SGD 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 56/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 56
How much profit the company makes from its sales and capital
Quality Growth 82
Are margins and returns getting better?
Cashflow 42
Do the profits arrive as real cash?
Financial strength 39
Debt, balance sheet and risk of trouble
Investment 34
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 25
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 20
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+21.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
Start year 2020 (pandemic). Over 10 years: +5.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+22.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−31% → 1%
⚠ Revenue per share shrinking 9.5%/yr over ~6Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −7.0% a year for the price.

Watch 505, get fair value alerts →

Compare ASIAMEDIC LIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks

Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside +12.2% · Top 25%
Profitability
Return on equity (12 months) 11.7% · Top 25%
Return on assets 6.1% · Top 25%
Net margin (12 months) 7.4% · Above median
Operating margin (12 months) 0.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) −2.5% · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 1.27× · Cheaper than median
P/S (12 months) 0.75× · Cheapest 25%
Price / free cash flow (fiscal year) 21.9× · Cheaper than median
EV/EBITDA 9.3× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)50 · sector 14
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)47 · sector 8
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥144.41 ¥164.66 +14% vs 505
IQVIA Holdings IQV $265.12 $291.63 +10% vs 505
Illumina, Inc ILMN $207.01 $227.71 +10% vs 505
Thermo Fisher Scientific Inc TMO $700.22 $686.04 −2% vs 505
Danaher Corporation DHR $233.02 $209.18 −10% vs 505
IDEXX Laboratories, Inc IDXX $704.23 $496.48 −30% vs 505
Lonza Group LONN CHF 670.20 CHF 259.80 −61% vs 505
Mettler-Toledo International Inc MTD $1,739 $655.06 −62% vs 505
Agilent Technologies, Inc A $173.96 $64.53 −63% vs 505
Waters Corporation WAT $460.25 $91.26 −80% vs 505

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ASIAMEDIC LIMITED: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ASIAMEDIC LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/505

Frequently asked questions

Is ASIAMEDIC LIMITED (505) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of 0.0202 SGD versus the last price from Nov 2, 2026 of 0.0180 SGD, about +12% upside (undervalued).
What is the fair value of 505?
Our model-based fair value for ASIAMEDIC LIMITED is 0.0202 SGD (as of Nov 13, 2026), built from audited fundamentals. Last price (from Nov 2, 2026): 0.0180 SGD.
What is the quality score of 505?
ASIAMEDIC LIMITED has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ASIAMEDIC LIMITED (505)?
Our model-based price target is the fair value of 0.0202 SGD (as of Nov 13, 2026) from 24 valuation models. Cautious scenario 0.0184 SGD, optimistic scenario 0.0238 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the ASIAMEDIC LIMITED stock forecast for 2026?
Our models put fair value at 0.0202 SGD, about +12% upside versus the last price from Nov 2, 2026 of 0.0180 SGD (undervalued). Cautious scenario 0.0184 SGD, optimistic scenario 0.0238 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of ASIAMEDIC LIMITED (505)?
ASIAMEDIC LIMITED reported trailing-twelve-month revenue of about 34.9M SGD (latest available figure, as of Nov 13, 2026).
What growth is priced into ASIAMEDIC LIMITED (505)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at ASIAMEDIC LIMITED shrinks by 5.1 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 18.2 % per year. As of Nov 13, 2026.
What discount rate (WACC) does the fair value of 505 use?
Our models discount ASIAMEDIC LIMITED at 8.3 %: a base by market capitalisation (nano), damped by beta 0.15, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ASIAMEDIC LIMITED that is -5.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has ASIAMEDIC LIMITED (505) delivered so far?
Over the past 5 years revenue at ASIAMEDIC LIMITED grew 18.2 % a year. The price currently implies free-cash-flow growth of -5.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ASIAMEDIC LIMITED (505) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into ASIAMEDIC LIMITED (-5.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ASIAMEDIC LIMITED (505)?
The free-cash-flow yield on the price is 5.91 %: that much free cash flow ASIAMEDIC LIMITED produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ASIAMEDIC LIMITED (505)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ASIAMEDIC LIMITED it is 0.0202 SGD per share (as of Nov 13, 2026), against a price of 0.0180 SGD. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is ASIAMEDIC LIMITED stock overvalued or undervalued in 2026?
As of Nov 13, 2026, 505 trades below its calculated fair value: price 0.0180 SGD, fair value 0.0202 SGD, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 505?
No. The price is what the market pays today (0.0180 SGD); the fair value is what the company's own numbers justify (0.0202 SGD). For ASIAMEDIC LIMITED the two are 0.0022 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is ASIAMEDIC LIMITED worth?
The market values ASIAMEDIC LIMITED at about 20.3M SGD (market capitalisation, as of Nov 13, 2026). Per share that is 0.0180 SGD; our models calculate a fair value of 0.0202 SGD per share.
What do the bullish and bearish scenarios say about 505?
Our models span a range for ASIAMEDIC LIMITED: cautious scenario 0.0184 SGD, base 0.0202 SGD, optimistic 0.0238 SGD per share (as of Nov 13, 2026, price 0.0180 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ASIAMEDIC LIMITED (505)?
Balance-sheet figures for ASIAMEDIC LIMITED (as of Nov 13, 2026): return on equity 11.7%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 505 from its 52-week high?
ASIAMEDIC LIMITED trades at 0.0180 SGD, about 33% below its 52-week high of 0.0270 SGD and 13% above the low of 0.0160 SGD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0202 SGD is for.
Which stocks are comparable to ASIAMEDIC LIMITED?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ASIAMEDIC LIMITED stock attractive at the current price?
The data as of Nov 13, 2026: price 0.0180 SGD, calculated fair value 0.0202 SGD (+12%), Quality Score 56/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 505 calculated?
We run ASIAMEDIC LIMITED through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.0202 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. ASIAMEDIC LIMITED currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ASIAMEDIC LIMITED (505)?
The latest price we hold is from Nov 2, 2026 and stands at 0.0180 SGD. Our model-based fair value is 0.0202 SGD, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ASIAMEDIC LIMITED right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits below our cautious bear case: the market assumes less than even our pessimistic scenario. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of ASIAMEDIC LIMITED

How large is the market capitalisation of ASIAMEDIC LIMITED (505)?
The market capitalisation of ASIAMEDIC LIMITED is 20.3M SGD (≈ $15.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ASIAMEDIC LIMITED (505)?
The price-to-sales ratio of ASIAMEDIC LIMITED is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ASIAMEDIC LIMITED (505)?
The net margin of ASIAMEDIC LIMITED is 5.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ASIAMEDIC LIMITED (505)?
The return on equity (ROE) of ASIAMEDIC LIMITED is 11.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ASIAMEDIC LIMITED (505)?
On an EBIT basis the return on assets of ASIAMEDIC LIMITED is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ASIAMEDIC LIMITED (505)?
The operating margin of ASIAMEDIC LIMITED is 0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ASIAMEDIC LIMITED (505)?
Revenue at ASIAMEDIC LIMITED is down 2.5% versus a year earlier (3y avg +23.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ASIAMEDIC LIMITED (505)?
Earnings per share at ASIAMEDIC LIMITED are growing 81.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch ASIAMEDIC LIMITED in the live analysis

One click puts ASIAMEDIC LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.